Feb. 6, 2003 (New Orleans) — In a head-to-head study comparing intra-articular hylan GF-20 injection (Synvisc) to corticosteroid injection for knee osteoarthritis, "there was no difference in outcome ...
(Recasts first paragraph; adds Genzyme comments, sales figures, competitors, byline; updates stock price) By Lisa Richwine GAITHERSBURG, Md., Dec 9 (Reuters) - A U.S. advisory panel has unanimously ...
The existing viscosupplements on the market in Japan require a greater number of injections than Synvisc, and may offer a much shorter duration of pain relief. Synvisc, the first non-Japanese ...
Please provide your email address to receive an email when new articles are posted on . The FDA has granted marketing approval to Genzyme Corp. for its Synvisc-One product indicated for the relief of ...
Genzyme Corporation today announced that the FDA's Orthopaedic and Rehabilitation Devices Advisory Committee voted unanimously (5 - 0) in favor of approval without conditions of Synvisc-One TM (hylan ...
WASHINGTON (Reuters) - A study of Genzyme Corp's latest version of its injectable knee pain treatment may be inadequate to weigh how well the product works, U.S. regulatory reviewers said in an ...
To earn CME related to this news article, click here. March 5, 2009 — The US Food and Drug Administration (FDA) has approved budesonide plus formoterol fumarate dihydrate inhalation aerosol for the ...
Please provide your email address to receive an email when new articles are posted on . The FDA Orthopaedic and Rehabilitation Devices Panel voted 5-0 Tuesday to recommend approving the premarket ...
Synvisc-One (hylan G-F 20, from Genzyme), has been FDAapproved for the relief of pain associated with osteoarthritis (OA) of the kneein patients who have failed to respond adequately to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results